65,437 trials
Otitis Media With Effusion
Primary: Absence of Middle Ear Fluid by Pneumatic Otoscopy, Right Ear — 1; 0 participants
Essential Hypertension ( Mild to Moderate)
Primary: Percentage of Participants (Defined as Estimated Cumulative Control Rate) Reaching Blood Pressure Target in a Stepped Care, Aliskiren-based Regimen — 86.12 Percentage of…
Pneumococcal Vaccine
Primary: Percentage of Participants Achieving a Serotype-specific Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (≥) 0.35 Micrograms Per Milliliter (Mcg/mL)…
Adenocarcinoma · Neoplasms
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs): Part 1 — 4; 5; 3; 7 participants
Hypertension
Primary: Overall Percentage of Patients With Adverse Events — 23.6; 71.2; 57.0 Percentage of Participants
Liver Transplantation
Primary: Incidence of Biopsy Proven Acute Rejection During the First 3 Months Post de Novo Liver Transplantation — 8; 26 Participants
Hepatitis C, Chronic · Hepatitis C
Primary: Number of Participants With Rapid Virologic Response After 4 Weeks of Treatment — 551; 32 Participants
Type 2 Diabetes Mellitus
Primary: Beta-cell Function After 52 Weeks of Therapy — 2.89; 1.15 ratio — p=0.0001
Hepatitis C, Chronic
Primary: Number of Study Participants Who Had a Virological Response (VR) at Week-72 — 176 Participants
Osteopenia
Primary: Percentage Change in Lumbar Spine Bone Mineral Density (BMD) at Month 24 Relative to Baseline, by Stratum — 4.62; 4.03; -2.24; 5.60 Percentage change in BMD
HIV Infections
Primary: Time From Randomization to Virologic Failure — 36; 24; 24; 24 Weeks
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Number of Patients With Response — 9; 21; 24 Participants
Hepatitis C, Chronic · Hepatitis C
Primary: Number of Hepatitis C Virus Ribonucleic Acid (HCV-RNA) Negative Participants at End of Therapy (EoT) — 1306 Participants
Bipolar Disorder · Schizophrenia
Primary: Number of Participants for Clinical Global Impression of Severity (CGI-S) Status at Final Visit (up to Week 8) - Intent to Treat Population — 190; 1125; 1325; 506…
Macular Degeneration · Age-related Macular Degeneration · Neovascular Macular Degeneration
Primary: Visual Acuity (VA) — 8.51; 8.72; 8.67; 8.93 lines of VA